

Optimi Health To Launch Therapeutic Psilocybin Product in Partnership With Patient Advocate Thomas Hartle

VANCOUVER, BC — [Optimi Health Corp.](#) (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms, as well as synthetic formulations for transformational human experiences, is pleased to announce that it has entered into a partnership with psilocybin patient advocate, Thomas Hartle. The parties have agreed to produce a Canadian-grown and harvested natural therapeutic psilocybin product for use by approved patients.

“Honouring Thomas’s incredible optimism and appreciation for life with his own natural, Canadian-grown psilocybin product is something we will cherish as a company forever,” said Bill Ciprick, CEO of Optimi Health. “We share Thomas’s energy and passion for creating the perfect psilocybin experience, and we look forward to providing a vital service to Special Access Program patients while further demonstrating to regulators that psychedelic-assisted therapies can be integrated into our existing healthcare framework.”

A virtual press conference is scheduled for **Wednesday, August 10, 2022 at 1:00 PM EST** where Optimi executives and Mr. Hartle will discuss details of the partnership and unveil the new product.

In commemoration of the two-year anniversary of Mr. Hartle being among Canada’s first applicants to be granted permission to undergo this ground-breaking treatment, Optimi has agreed to make a financial donation towards his newly established charitable enterprise. Further, the Company will donate the proceeds from product sales directly to Mr. Hartle’s charity for the purpose of facilitating patient access to psilocybin-assisted therapy.

“Honestly, until I started receiving my psilocybin-assisted therapy treatments two years ago, I wasn’t sure if I could handle the daily stress of knowing that I was dying,” said Hartle. “Having a therapeutic psilocybin product made in my honour, which I had never considered as a possibility, gives me pause to reflect on how many have lost their battles before ever experiencing the amazing benefits of psilocybin therapy. I am excited to be partnering with Optimi to provide that opportunity to the people who need it most, with the hope that they will receive the same life restoring gift that I have experienced.”

Hartle’s charitable vision will address equality and the inherent lack of access to psilocybin-assisted therapy for vulnerable and underserved populations, something Optimi sees as a critical component of the new partnership agreement.

“Vulnerable and underserved adults who are often excluded from the benefits of psilocybin therapy based on social, economic, gender, and racial factors beyond their control is a problem we need to solve,” added Ciprick. “Pain doesn’t discriminate, so hopefully our announcement with Thomas is a step in the right direction in addressing this urgent need.”

Mr. Hartle will provide more details on his charity at the August 10, 2022 virtual press conference.

To access the press conference or to receive an advanced media kit with product specifications, please contact Michael Kydd at michael@kyddergroup.com or 902.880.621.

Marketing Services

Optimi has also, effective on August 10, 2022, entered into a six-month service agreement with Native Ads, Inc., which will provide the Company with strategic digital media services, marketing and data analytics services. These can include sponsored articles and other advertising development, ad campaign analytics and media buying and distribution services.

The agreement is renewable at the Company's option.

ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)

Optimi Health Corp. is a Health Canada licensed, homegrown Canadian success story producing and supplying natural, EU-GMP grade psilocybin and synthetic psychedelic substances, as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable, natural mushroom formulations for transformational human experiences, the Company's goal is to be the number one trusted, passionate supplier of safe, natural EU-GMP psilocybin and synthetic psychedelics throughout the world. With a vertically integrated approach, Optimi is engaged in the cultivation, extracting, processing and distribution of high quality functional and psychedelic mushroom products at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia.

ABOUT THOMAS HARTLE

Thomas Hartle is a 54-year-old husband, father, and IT professional who was diagnosed with stage 4 colon cancer in 2016. Faced with the typical outcome of stage 4 cancer, Thomas experienced a debilitating level of anxiety over his future, as well as that of his family. This anxiety prompted him to explore new potential options for his treatment-resistant condition. In August of 2020, Thomas became the first Canadian to legally receive psilocybin-assisted psychotherapy.

Since that time, Thomas has experienced a substantial improvement in both his emotional wellbeing and his overall ability to once again enjoy the time he has with his family. He is currently advocating the use of this therapy while undergoing his regular cancer treatment regime.

FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, "forward-looking statements") that relate to Optimi's current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as "will likely result," "are expected to," "expects," "will continue," "is anticipated," "anticipates," "believes," "estimated," "intends," "plans," "forecast," "projection," "strategy," "objective," and "outlook") are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news

release. In particular and without limitation, this news release contains forward- looking statements pertaining to activities proposed to be conducted under the Company's dealer's license and associated business related to Psilocybin and Psilocin and Optimi's plans, focus and objectives.

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID-19 pandemic and other factors set forth under "Forward-Looking Statements" and "Risk Factors" in the Company's Annual information Form dated January 12, 2022, and other continuous disclosure filings available under Optimi's profile at www.sedar.com. Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement.

Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

For Further Information, Contact:

Investor Relations

investors@optimihealth.ca

www.optimihealth.ca

For Media Inquiries, Contact:

Kydder Group Inc.

Michael@kyddergroup.com

1.902.880.6121